Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 13.04 AUD -0.91% Market Closed
Market Cap: 652.8m AUD
Have any thoughts about
Clinuvel Pharmaceuticals Ltd?
Write Note

Intrinsic Value

The intrinsic value of one CUV stock under the Base Case scenario is 18.56 AUD. Compared to the current market price of 13.04 AUD, Clinuvel Pharmaceuticals Ltd is Undervalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CUV Intrinsic Value
18.56 AUD
Undervaluation 30%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Clinuvel Pharmaceuticals Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CUV cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CUV?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Clinuvel Pharmaceuticals Ltd

Provide an overview of the primary business activities
of Clinuvel Pharmaceuticals Ltd.

What unique competitive advantages
does Clinuvel Pharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Clinuvel Pharmaceuticals Ltd face in the near future?

Has there been any significant insider trading activity
in Clinuvel Pharmaceuticals Ltd recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Clinuvel Pharmaceuticals Ltd.

Provide P/S
for Clinuvel Pharmaceuticals Ltd.

Provide P/E
for Clinuvel Pharmaceuticals Ltd.

Provide P/OCF
for Clinuvel Pharmaceuticals Ltd.

Provide P/FCFE
for Clinuvel Pharmaceuticals Ltd.

Provide P/B
for Clinuvel Pharmaceuticals Ltd.

Provide EV/S
for Clinuvel Pharmaceuticals Ltd.

Provide EV/GP
for Clinuvel Pharmaceuticals Ltd.

Provide EV/EBITDA
for Clinuvel Pharmaceuticals Ltd.

Provide EV/EBIT
for Clinuvel Pharmaceuticals Ltd.

Provide EV/OCF
for Clinuvel Pharmaceuticals Ltd.

Provide EV/FCFF
for Clinuvel Pharmaceuticals Ltd.

Provide EV/IC
for Clinuvel Pharmaceuticals Ltd.

Show me price targets
for Clinuvel Pharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Clinuvel Pharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Clinuvel Pharmaceuticals Ltd?

What are the Net Income projections
for Clinuvel Pharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Clinuvel Pharmaceuticals Ltd?

What are the EPS projections
for Clinuvel Pharmaceuticals Ltd?

How accurate were the past EPS estimates
for Clinuvel Pharmaceuticals Ltd?

What are the EBIT projections
for Clinuvel Pharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Clinuvel Pharmaceuticals Ltd?

Compare the revenue forecasts
for Clinuvel Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Clinuvel Pharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Clinuvel Pharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Clinuvel Pharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Clinuvel Pharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Clinuvel Pharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Clinuvel Pharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Clinuvel Pharmaceuticals Ltd.

Provide ROE
for Clinuvel Pharmaceuticals Ltd.

Provide ROA
for Clinuvel Pharmaceuticals Ltd.

Provide ROIC
for Clinuvel Pharmaceuticals Ltd.

Provide ROCE
for Clinuvel Pharmaceuticals Ltd.

Provide Gross Margin
for Clinuvel Pharmaceuticals Ltd.

Provide Operating Margin
for Clinuvel Pharmaceuticals Ltd.

Provide Net Margin
for Clinuvel Pharmaceuticals Ltd.

Provide FCF Margin
for Clinuvel Pharmaceuticals Ltd.

Show all solvency ratios
for Clinuvel Pharmaceuticals Ltd.

Provide D/E Ratio
for Clinuvel Pharmaceuticals Ltd.

Provide D/A Ratio
for Clinuvel Pharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Clinuvel Pharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Clinuvel Pharmaceuticals Ltd.

Provide Quick Ratio
for Clinuvel Pharmaceuticals Ltd.

Provide Current Ratio
for Clinuvel Pharmaceuticals Ltd.

Provide Cash Ratio
for Clinuvel Pharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Clinuvel Pharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Clinuvel Pharmaceuticals Ltd?

What is the current Free Cash Flow
of Clinuvel Pharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Clinuvel Pharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Clinuvel Pharmaceuticals Ltd

Current Assets 222.1m
Cash & Short-Term Investments 183.9m
Receivables 26.2m
Other Current Assets 12m
Non-Current Assets 9.1m
PP&E 7.7m
Intangibles 185k
Other Non-Current Assets 1.2m
Current Liabilities 25.2m
Accounts Payable 7.1m
Other Current Liabilities 18.1m
Non-Current Liabilities 2.9m
Long-Term Debt 509.9k
Other Non-Current Liabilities 2.4m
Efficiency

Earnings Waterfall
Clinuvel Pharmaceuticals Ltd

Revenue
95.5m AUD
Cost of Revenue
1.1m AUD
Gross Profit
96.6m AUD
Operating Expenses
-39.5m AUD
Operating Income
57.1m AUD
Other Expenses
-21.4m AUD
Net Income
35.6m AUD

Free Cash Flow Analysis
Clinuvel Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CUV Profitability Score
Profitability Due Diligence

Clinuvel Pharmaceuticals Ltd's profitability score is 78/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Positive Gross Profit
Positive Operating Income
78/100
Profitability
Score

Clinuvel Pharmaceuticals Ltd's profitability score is 78/100. The higher the profitability score, the more profitable the company is.

CUV Solvency Score
Solvency Due Diligence

Clinuvel Pharmaceuticals Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Clinuvel Pharmaceuticals Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CUV Price Targets Summary
Clinuvel Pharmaceuticals Ltd

Wall Street analysts forecast CUV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CUV is 26.93 AUD with a low forecast of 17.17 AUD and a high forecast of 41.58 AUD.

Lowest
Price Target
17.17 AUD
32% Upside
Average
Price Target
26.93 AUD
107% Upside
Highest
Price Target
41.58 AUD
219% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CUV?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CUV is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CUV Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd

Country

Australia

Industry

Biotechnology

Market Cap

653m AUD

Dividend Yield

0.38%

Description

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.

Contact

VICTORIA
Melbourne
L 11 535 Bourke St
+61396604900.0
www.clinuvel.com

IPO

2001-02-13

Employees

-

Officers

CEO, MD & Director
Dr. Philippe Jacques Wolgen M.B.A., M.D.
Chief Scientific Officer
Dr. Dennis J. Wright BPharm, M.Sc., Ph.D.
Chief Financial Officer
Mr. Peter Vaughan
Chief Operations Officer
Mr. Lachlan Hay
Head of Australian Operations & Investor Relations
Mr. Malcolm Bull
Senior Vice President of Regulatory Affairs
Dr. Rose Quadbeck-Diel
Show More
Head of Quality Assurance & Drug Safety
Dr. Azza Hamila
Company Secretary
Ms. Claire Newstead-Sinclair C.A.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CUV stock?

The intrinsic value of one CUV stock under the Base Case scenario is 18.56 AUD.

Is CUV stock undervalued or overvalued?

Compared to the current market price of 13.04 AUD, Clinuvel Pharmaceuticals Ltd is Undervalued by 30%.

Back to Top